| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Special Feature |
Departments of Pediatrics and Radiology (Division of Nuclear Medicine), Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242
Address all correspondence and requests for reprints to: Dr. Charles H. Read, 3 Glenview Knoll NE, Iowa City, Iowa 52240-9146. E-mail: charlesread{at}msn.com.
This report details the 26- and 36-yr outcomes of 116 patients under the age of 20 yr with Graves’ disease who were treated with radioiodine between 1953 and 1973. Contacted by telephone and mail in 1991–1992, 107 of them supplied personal historical data, and their physicians furnished interval histories, physical examinations, and laboratory data. This was repeated in 2001–2002, with 98 of them being contacted. At the time of treatment, the patients’ ages ranged between 3 yr, 7 months and 19 yr, 9 months. Six were less than 6 yr of age, 11 were between 6 and 11 yr, 45 were between 11 and 15 yr, and 45 were between 16 and 19 yr. The average length of follow-up in 1991–1992 was 26.1 yr; that in 2001–2002 was 36.2 yr. None of the patients developed cancer of the thyroid or leukemia. Early on, when the objective of treatment was euthyroidism, the dose of radioiodine was low, and retreatment was frequently needed. Later, the doses used were increased. Over time, all but two patients became hypothyroid. Pregnancies did not result in an unusual number of congenital anomalies or spontaneous abortions. Treating young people with Graves’ disease with radioiodine is safe and effective over the long term.
This article has been cited by other articles:
 |
|
 |
|
  N. S. Glaser, D. M. Styne, and for the Organization of Pediatric Endocrinologists Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study Pediatrics, March 1, 2008; 121(3): e481 - e488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Focosi, S. Galimberti, and M. Petrini Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases Haematologica, September 1, 2007; 92(9): e96 - e97. [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Rivkees and C. Dinauer An Optimal Treatment for Pediatric Graves' Disease Is Radioiodine J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 797 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Lee, M. M. Grumbach, and O. H. Clark The Optimal Treatment for Pediatric Graves' Disease Is Surgery J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 801 - 803. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Iagaru and I. R. McDougall Treatment of Thyrotoxicosis J. Nucl. Med., March 1, 2007; 48(3): 379 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Dharmaraj and A Grueters The management of thyrotoxicosis in a pre-pubertal child with 18p deletion syndrome Eur. J. Endocrinol., November 1, 2006; 155(suppl_1): S145 - S147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Kincaid, L. S. Nield, D. Hsieh, R. Friederich, M. M. Pelszynski, F. Mule, and K. Roberts Index of suspicion. Pediatr. Rev., August 1, 2006; 27(8): 307 - 313. [Full Text] [PDF]
|
|
|
|
 |
|
 Radioiodine therapy for hyperthyroidism DTB, June 1, 2006; 44(6): 44 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Goichot, S. Vinzio, E. Lubin, T. D. Nebesio, E. A. Eugster, P. J.J. Admiraal, and D. S. Cooper Antithyroid Drugs N. Engl. J. Med., May 26, 2005; 352(21): 2246 - 2247. [Full Text] [PDF]
|
|
|
|
|
|
S. Rivkees Radioactive Iodine Use in Childhood Graves' Disease: Time to Wake Up and Smell the I-131 J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4227 - 4228. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
